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Altered peptide ligands (APLs) provide useful tools to studyT cell activation and potentially
direct immune responses to improve treatment of cancer patients.To better understand and
exploit APLs, we studied the relationship between APLs andT cell function in more detail.
Here, we tested a broad panel of gp100280–288 APLs with respect toT cell cytotoxicity, pro-
duction of cytokines, and activation of Nuclear Factor of ActivatedT cells (NFAT) by humanT
cells gene-engineered with a gp100-HLA-A2-specificTCRαβ.We demonstrated that gp100-
specific cytotoxicity, production of cytokines, and activation of NFAT were not affected by
APLs with single amino acid substitutions, except for an APL with an amino acid substitu-
tion at position 3 (APL A3), which did not elicit anyT cell response. A gp100 peptide with a
double amino acid mutation (APL S4S6) elicited T cell cytotoxicity and production of IFNγ,
and to a lesser extent TNFα, IL-4, and IL-5, but not production of IL-2 and IL-10, or activation
of NFAT. Notably, T cell receptor (TCR)-mediated functions showed decreases in sensitivi-
ties for S4S6 versus gp100 wild-type (wt) peptide, which were minor for cytotoxicity but at
least a 1000-fold more prominent for the production of cytokines. TCR-engineered T cells
did not bind A3-HLA-A2, but did bind S4S6-HLA-A2 although to a lowered extent compared
to wt peptide-HLA-A2. Moreover, S4S6-inducedT cell function demonstrated an enhanced
dependency on CD8α.Taken together, most gp100 APLs functioned as agonists, but A3 and
S4S6 peptides acted as a null ligand and partial agonist, respectively. Our results further
suggest thatTCR-mediated cytotoxicity can be dissected from production of cytokines and
activation of NFAT, and that the agonist potential of peptide mutants relates to the extent
of binding by TCR and CD8α. These findings may facilitate the design of APLs to advance
the study of T cell activation and their use for therapeutic applications.
Keywords: activation of nuclear factor of activatedT cells, altered peptide ligands, cytokine production, cytotoxicity,
humanT lymphocytes,T cell receptor
INTRODUCTION
T lymphocytes are potent mediators of anti-tumor immune
responses. In fact, T cell receptor (TCR) genes derived from anti-
tumor T lymphocytes have been successfully used to redirect other,
non-tumor-specific T lymphocytes to tumor cells, and have shown
promising clinical activities in the treatment of tumor-bearing
patients (1, 2). Adoptive T cell therapy to tumors is based on the
ability of TCRs to selectively recognize antigens, i.e., peptides that
are presented by Major Histocompatibility Complex (MHC) mol-
ecules. The clinical use of TCR-engineered T lymphocytes directed
against the human leukocyte antigen (HLA)-A2-restricted anti-
gens MART-1, gp100, or NY-ESO-1 resulted in objective responses
in patients with metastatic melanoma up to 45% (3, 4). Impor-
tantly, the avidity and antigen reactivity of parental T cell clones,
used as a source for TCR genes, are preserved by TCR gene trans-
fer (5–7). Moreover, cytotoxic responses of TCR-engineered T cells
toward a panel of gp100 peptide mutants are identical to those of
parental CTL clones (7).
Studies with mutated peptides, so called altered peptide ligands
(APLs), have eloquently demonstrated that T cell recognition of
antigen is flexible and that binding of different APLs can result
in distinct and selective T cell signaling and functions (8, 9).
APLs can be classified depending on the T cell responses they
elicit; e.g., agonists induce the full range of T cell activation such
as proliferation, cytokine secretion, and cytotoxic killing; partial
agonists sub-optimally activate T cells and cause a selective pat-
tern of effector functions; null agonists do not activate T cells;
whereas antagonists specifically inhibit T cell activation induced
by the wild-type (wt) peptide [reviewed in (10, 11)]. Interest-
ingly, melanoma cells can process and present antagonistic APLs
themselves, thereby potentially providing cues that prevent maxi-
mal intra-tumoral T cell activation and facilitate immune evasion
(12). Immune suppression mediated by antagonistic peptide vari-
ants can be reversed by APLs with highly agonist properties that
are able to sensitize T cells and yield resistance against effects of
inhibitory APLs (12, 13). Importantly, APLs have already been
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used in immunotherapeutic strategies with the intent to more
effectively skew immune responses against autoimmune diseases,
infectious diseases, and cancer [reviewed in (10)].
Numerous APLs have been designed for cancer epitopes and
include, amongst others, MUC1-HLA-A2 (14), HER1-HLA-A2
(15), HER2-HLA-A2 (16), HER2-HLA-A24 (17), MelanA-HLA-
A2 (18), gp100-HLA-A2 [epitopes 154, 209, and 280 (19)], TRP2-
HLA-A2 (20), PSA-HLA-A2 (21), and NY-ESO1-HLA-A2 (22).
Such APLs have principally been designed to improve the bind-
ing affinity of peptide to the MHC molecule, allowing induction
of improved T cell responses against wt epitope. For example,
MelanA-HLA-A2-specific T cell responses have rapidly and repro-
ducibly been induced with the highly immunogenic APL with a
Leucine at anchor position 2 (L2) (18, 23). However, enhanced
immunogenicity of APLs may not necessarily be accompanied by
the induction of a curative T cell response specific for the native
epitope in patients with cancer. In fact, the modified MelanA
epitope may alter TCR binding and prime T cells with differ-
ent TCRs compared to the wt peptide (24). Indeed in patients
with melanoma, T cells elicited by APL L2 demonstrated higher
frequencies but weaker functional T cell avidity toward the native
epitope (25). This is not necessarily a general finding as gp100 APLs
(gp100154–162 A8 and gp100280–288 V9) were clinically equally
effective when compared to wt peptides when used in combina-
tion with a DC vaccine (26). Collectively, however, these studies
challenge the value and clinical applicability of APLs. Further and
detailed studies into APLs and their effects on various T cell para-
meters are needed to gain a better understanding of the perimeters
of T cell specificity and sensitivity. In addition, a correct defini-
tion of agonist and potential antagonist properties of APLs will
allow successful translation of selected APLs to clinical settings.
It is noteworthy that besides the setting of vaccination, where the
frequency of the relevant TCR may be insufficient, the clinical
potential of APLs may be extended to the setting of adoptive T cell
therapy, which ensures a high frequency of the expected TCR in
patients.
Here, we have used a panel of gp100280–288 APLs and explored
APL characteristics in relation to T cell recognition and different
T cell responses. To this end, we have transferred a defined TCR,
i.e., a gp100-HLA-A2-specific TCR, into human T cells, and tested
the effect of individual and double amino acid substitutions of
the wt gp100 peptide on T cell responses. Analyses of gp100 APLs
revealed that all single amino acid mutants retain their agonistic
properties, except for the A3 mutant and double amino acid S4S6
mutant that acted as a null ligand and partial agonist, respectively.
Findings showed that TCR-mediated cytotoxicity can be dissected
from production of cytokines and activation of nuclear factor of
activated T cells (NFAT), and suggest that the agonist potential
of APLs relates to the extent a peptide mutant is bound by TCR
and CD8α.
MATERIALS AND METHODS
CELLS AND REAGENTS
Peripheral blood lymphocytes (PBL) from healthy donors
were isolated by centrifugation through Ficoll-Isopaque (den-
sity= 1.077 g/cm3; Pharmacia Biotech, Uppsala, Sweden).
Obtaining and handling of human samples, such as PBL, were
according to national and institutional guidelines and approved
by the Erasmus MC Cancer Institute’s ethical committee. Pri-
mary human T lymphocytes were cultured as described elsewhere
(7). The TAP-deficient TxB cell hybrid and HLA-A2-positive
T2, and the gp100-positive, HLA-A2-positive melanoma cell line
FM3 were maintained in DMEM (Gibco BRL, Paisley, Scotland,
UK) supplemented with 10% Bovine Calf Serum (BCS: Hyclone,
Logan, UT, USA) and the antibiotics streptomycin (100µg/ml)
and penicillin (100 U/ml). The HLA-A2-positive melanoma cell
lines BLM and BLMgp100 (the latter transfected with human
gp100-encoding cDNA) were cultured as described previously
(27, 28). The Jurkat T cell clone E6.1 was expanded in RPMI
1640 medium supplemented with l-glutamine, 10% BCS, and
antibiotics.
PEPTIDES AND PEPTIDE-MHC MULTIMERS
Peptides used in this study were: the gp100280–288 wt peptide
YLEPGPVTA, the gp100 APLs A1–A8, G9, and S4S6, indicat-
ing an Alanine, Glycine, or Serine substitution at the indi-
cated amino acid position of the wt peptide, and an irrele-
vant HLA-A2-binding EBV BMLF-1 wt peptide (GLCTLVAML).
Peptide preparations were synthesized as described earlier (7)
and found to be >90% pure as analyzed by analytical HPLC.
MHC class I binding of peptides was analyzed via stabiliza-
tion of HLA-A2 on T2 cells, as described previously (29, 30).
The gp100 wt peptide, the gp100 APLs A3 and S4S6, and
the BMFL-1 wt peptide were used to generate peptide-HLA-
A2 monomers (Sanquin Blood Supply Foundation, Amsterdam,
Netherlands). Multimers of peptide and HLA-A2 were freshly
prepared by incubating streptavidinPE and the corresponding sol-
uble monomers at a 1:4 molar ratio for 1 h at 4°C as described
elsewhere (31).
CLONING AND TRANSFER OF TCR GENES
Genes encoding gp100280–288-HLA-A2-specific TCRαβwere PCR-
amplified from CTL clone 296 (CTL-296) and cloned into the
retroviral vector bullet, as described previously (7). Primary
human T lymphocytes of healthy donors, pre-activated with anti-
CD3 mAbs were transduced with TCR-positive retroviruses pro-
duced by the packaging cell line Phoenix-Amp (32,33). A retroviral
vector encoding human CD8α (34) was used to transduce Jurkat T
cells prior to transfer of TCR genes (35). Transduction with Mock
genes served as a negative control.
FLOW CYTOMETRY AND CELL-SORTING
T cells were analyzed for TCR transgene expression by flow
cytometry using either PE-conjugated anti-TCRVβ27 mAb
(Beckman-Coulter, Marseille, France) (nomenclature of TCRV
regions according to http://imgt.org) or PE-conjugated gp100 wt
peptide-HLA-A2 complexes (ProImmune Ltd., Oxford, UK), as
described previously (7, 35). In short, 0.1–0.5× 106 T cells were
incubated with mAb on ice for 30 min or peptide-MHC complexes
(see Peptides and Peptide-MHC Multimers) at room temperature
for 1 h, washed, fixed (1% PFA). T cells were gated according to for-
ward and sideward scatter properties using a FACSCalibur (Becton
Dickinson, Alphen a/d Rijn, Netherlands) equipped with Cell-
Quest software (BD Biosciences). Binding of peptide-MHC was
Frontiers in Immunology | T Cell Biology September 2013 | Volume 4 | Article 270 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schaft et al. APLs dissect T cell functions
analyzed within viable gate of TCR-engineered T cells with marker
set at <1% positive binding for non-stained TCR-engineered T
cells. TCR-engineered T cells were MACS-enriched using gp100
wt peptide-HLA-A2 multimers and anti-PE MACS MicroBeads
according to the manufacturer’s instructions (Miltenyi Biotec,
Bergisch Gladbach, Germany).
CYTOTOXICITY ASSAY
Cytotoxic activity of T cells was assayed in standard 6 h 51Cr-release
assays using the following target cells: T2 cells pulsed with 1µM or
titrated amounts of either gp100 wt peptide, gp100 APLs, BMLF-1
wt peptide, or the melanoma cell lines BLM, BLMgp100, or FM3.
Antigen-specificity was confirmed by addition of anti-TCRVβ27
mAb or mouse immunoglobulin (mIg; Jackson ImmunoResearch
Laboratories, West Grove, PA, USA) (both at 1µg/ml final), and
the contribution of CD8 interactions was studied by addition of
anti-CD8α mAb (clone 4H8, 10µg/ml final, Sanquin Blood Sup-
ply Foundation) to T cells 30 min before cultivation with target
cells. To inhibit NK cell activity during the cytotoxicity assay,
an excess of non-labeled K562 cells was added to target cells
prior to assay. The percentage of specific 51Cr-release was deter-
mined as follows: [(test counts− spontaneous counts)/(maximum
counts− spontaneous counts)]× 100% (36).
CYTOKINE MEASUREMENTS
To quantify the production of cytokines, 6× 104 T cells were cul-
tured in the presence of 2× 104 T2 cells pulsed with titrated
amounts of peptide for 18 h. Supernatants were harvested, and
levels of IL-2, IL-4, IL-5, IL-10, IFNγ, and TNFα were determined
via Cytokine Bead Array (CBA kit; BD Biosciences), according to
the manufacturer’s instructions. In some experiments, CBA data
were supplemented with ELISAs (Sanquin Blood Supply Foun-
dation), which were performed according to the manufacturer’s
instructions. As a positive control, T cells were stimulated with
PMA and PHA.
NFAT REPORTER GENE ASSAY
Reporter gene assays for NFAT were performed as described in
detail elsewhere (35). In short, exponentially growing TCR/CD8-
co-transduced Jurkat T cells (5× 106) were electroporated with a
construct containing Firefly Luciferase coupled to six response
elements of NFAT [FLuc-NFAT(RE)6]. Twenty hours post-
transfection, Jurkat T cells were transferred to round-bottom 96-
well plates at 2× 105 cells/well and co-incubated with target cells
at 105 cells per well for 6 h in RPMI 1640 medium supplemented
with 1% BCS at 37°C and 5% CO2. FM3 cells were pre-incubated
O/N with IFNγ (PeproTech, NJ, USA, 10 ng/ml) and IL-1β (Pepro-
Tech, 30 ng/ml), and co-cultivation of these melanoma cells with
Jurkat T cells was performed in the presence of anti-CD28 mAb
(clone 15E8, 2µg/ml, Sanquin Blood Supply Foundation). As a
positive control for activation of NFAT, T cells were stimulated
with PMA and ionomycin. Following stimulation, cells were lysed
and luciferase activities were determined. Luciferase activities were
expressed relative to a non-stimulated condition (medium only,
which was set to 1.0; Figure 1) or in absolute light units corrected
for a non-stimulated condition (LU corrected for medium only;
Figure 5).
PRESENTATION OF THE DATA
All assays, i.e., cytotoxicity, cytokine production, and NFAT acti-
vation assays have at least three data points of which mean values
(with all values within 15% of mean) were used for graphical pre-
sentation. For each graph the experiment as a whole was repeated
several times (as indicated) and data of a representative experi-
ment was shown (the latter based on the mean value of triplicate
data points per experiment).
RESULTS
SINGLE AMINO ACID SUBSTITUTIONS OF THE gp100 wt PEPTIDE DO
NOT AFFECT T CELL FUNCTIONS EXCEPT FOR E3 TO A SUBSTITUTION,
WHICH RESULTS IN A NULL LIGAND
In order to study gp100 peptide requirements of various TCR-
mediated responses, both primary human T cells and Jurkat
T cells were retrovirally transduced with TCR α and β genes
that originated from the gp100/HLA-A2-specific CTL clone 296,
and MACsorted for high and equal levels of TCR expression.
Flow cytometry with TCRVβ mAb showed that gp100 TCR
expression levels were about 90% [mean fluorescence intensity
(MFI): 103] and 93% (MFI: 214) for primary human T lym-
phocytes and Jurkat T cells, respectively (data not shown). CD8
expression on primary human T cells was >50% and Jurkat T
cells were co-transduced with the human CD8α gene (expres-
sion level: 100%; MFI: 590) (data not shown). Antigen-specific
responses of TCR-engineered T cells were validated at the level
of T cell cytotoxicity, production of TNFα, and activation of
NFAT. Figure 1A demonstrates that TCR-transduced primary
human T lymphocytes were able to lyse gp100-positive, HLA-
A2-positive but not gp100-negative, HLA-A2-positive melanoma
cell lines. The antigen-specificity of this response was further
confirmed by the use of anti-TCRVβ mAb (Figure 1A). In addi-
tion, Figures 1B,C demonstrate that TCR-transduced human
T lymphocytes produced TNFα and activated the transcription
factor NFAT in an antigen-specific manner. Mock-transduced
T cells did not show cytotoxic reactivities, TNFα production,
and NFAT activation in response to any of the tumor cell lines
tested. Data shown in Figure 1 confirm previous data from
our group (7, 35) and further validate the antigen-specificity
and use of the CTL296-derived TCRαβ for our in vitro analyses
of APLs.
Using APLs with single amino acid substitutions, we studied
the same three T cell responses with the following observations.
First, all APLs (n= 9) sensitized T2 target cells for TCR-mediated
lysis, except for APL with an E to A substitution at position 3
(i.e., APL A3) (Figure 2A). Second, although quantities of TNFα
produced varied depending on the peptide used, all APLs, except
for APL A3, induced production of this cytokine (Figure 2B).
Third, again all APLs induced a clear activation of NFAT, except
for APL A3 (Figure 2C). Mock-transduced T cells did not respond
upon stimulation with any of the APLs tested, neither did TCR-
transduced T cells respond to stimulation with BMLF-1 wt pep-
tide (data not shown and Figure 2). Observations presented in
Figure 2 extend earlier data showing that the cytotoxic responses
of the parental CTL-296 versus gp100 APL with single amino acid
mutations are preserved following TCR gene transfer into human
T cells (7).
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FIGURE 1 |T cells gene-engineered with a gp100/HLA-A2-specificTCR
demonstrate antigen-specific reactivity against melanoma cells.
(A) TCR-transduced human T cells lyse gp100-positive, HLA-A2-positive
melanoma cells. Primary human T cells transduced with TCR (black bars) or
Mock genes (white bars) were tested in a 6 h 51Cr-release assay with the
following target cells: the gp100-negative, HLA-A2-positive melanoma cell
line BLM and the gp100-positive, HLA-A2-positive melanoma cell lines
BLMgp100 and FM3. The effector to target cell ratio was 30:1. Inhibition
studies were performed with T cells and FM3 target cells using
anti-TCRVβ27 mAb (Vb27) or mIg. Specific lysis was calculated, and results
of one (out of three) representative experiment are shown.
(B) TCR-transduced human T cells produce TNFα in response to
gp100-positive, HLA-A2-positive melanoma cells.
(Continued)
FIGURE 1 | Continued
T cells and melanoma cells as described in (A) were co-cultivated for 18 h at
an effector to target cell ratio of 3:1, after which TNFα levels (in pg/ml) were
determined in supernatants by ELISA. Results of one (out of three)
representative experiment are shown. (C) TCR-transduced human T cells
activate NFAT in response to gp100-positive, HLA-A2-positive melanoma
cells. Jurkat T cells transduced with TCR (black bars) or Mock genes (white
bars) were transfected with an NFAT reporter construct and subsequently
co-cultivated for 6 h with the same target cells as described in (A) at an
effector to target cell ratio of 2:1. Luciferase activities were determined in
cell lysates and expressed relative to medium only [in Relative Light Units
(RLU)]. Medium stimulations of TCR- and Mock-transduced Jurkat T cells
were 0.024 and 0.018, respectively, and were both set to 1.0. Results of
one (out of two) representative experiment are shown.
A P4 AND P6 TO S SUBSTITUTION VARIANT OF THE gp100 wt PEPTIDE
FUNCTIONS AS A PARTIAL AGONIST AND DISSECTS T CELL
CYTOTOXICITY FROM PRODUCTION OF CYTOKINES AND ACTIVATION
OF NFAT
Next to the gp100 APLs with single amino acid substitutions, we
generated an APL with a double amino acid mutation. The ratio-
nale behind designing this APL was to experimentally address
whether replacement of both Proline amino acids, which are
characterized by a rigid backbone, would affect and perhaps
enhance T cell functions. Since Prolines at positions 4 and 6 in
the wt gp100 peptide (YLEPGPVTA), when individually replaced
by Alanine, did not alter function of T cells, we next replaced
both Prolines by Serines, which are characterized by a more
flexible backbone. This S4S6 peptide, when tested in the same
set of assays as described above, was able to induce a cyto-
toxic T cell response and production of low levels of TNFα, but
was not able to induce activation of NFAT in human T cells
(Figures 2A–C).
Findings with gp100 APLs suggest that APLs A1, A2, A4, A5, A6,
A7,A8, G9 act as full agonists; APL A3 acts as a null ligand; and APL
S4S6 acts as a partial agonist (Figure 2). To verify whether APLs A3
and S4S6 present a true null ligand and partial agonist, respectively,
we performed extensive peptide dose-response studies. Results
of repeated experiments were highly consistent and showed that
APL A3 did not elicit T cell cytotoxicity (Figure 3), production
of cytokines (Figure 4), and activation of NFAT (Figure 5) when
tested over a 7-log range of peptide concentrations (10−5–10−12 M
peptide). APL S4S6, however, induced decreased T cell cytotox-
icity (Figure 3), an extremely lowered production of cytokines
(Figure 4), but no activation of NFAT (Figure 5). When looking
at wt peptide, we noted that over a large range of concentrations,
T cell responses were comparable in all three assays, arguing that
results with APLs are not due to differences in assay sensitivi-
ties. In example, wt peptide induced maximal T cell cytotoxicity,
IFNγ production as well as NFAT activation over a 4-log range
(10−5–10−8 M peptide), whereas these T cell responses became
suboptimal from 10−9 to 10−10 M peptide onward, and were neg-
ligible from 10−10 to 10−11 M or lower. Instead, quantities of
S4S6 peptide that were able to induce maximal T cell cytotoxicity
were 10–100-fold higher when compared to wt peptide (Figure 3).
With respect to cytokines, wt peptide selectively induced levels
of IFNγ, and to a lesser extent TNFα, IL-2, IL-4, and IL-5, but
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FIGURE 2 | gp100 APLs with single amino acid substitutions function
as full agonists except for APL A3, which functions as a null ligand.
Human T cells transduced with gp100/HLA-A2 TCR genes were tested in
(A) 51Cr-release, (B) TNFα production, and (C) NFAT reporter gene assays.
Target cells used were T2 cells that were pre-incubated with 1µM of gp100
wt peptide (wt), gp100 APLs A1–A8, and G9, or BMLF-1 wt peptide (irr.
pept.). gp100 APLs are encoded as indicated in the Section “Materials and
Methods.” In the 51Cr-release, TNFα production, and NFAT reporter gene
assays, the effector to target cell ratios were 15:1, 3:1, and 2:1,
respectively. T cell responses in all three assays are expressed relative to T2
target cells pulsed with gp100 wt peptide (specific lysis: 80%; production
of TNFα: 1015 pg/ml; and activation of NFAT: 34.73 RLU, all set to 100%).
Mock-transduced human T cells did not show activity in response to gp100
APLs (data not shown). Results of one (out of three) representative
experiment are shown based on the mean value of triplicate data points.
Note the null responses of the gp100 APL A3.
FIGURE 3 |The gp100 APL S4S6 is able to induceT cell cytotoxicity.
TCR-engineered T cells were tested in a 51Cr-release assay. T2 target cells
were either non-loaded or loaded with titrated amounts of gp100 wt peptide
(wt) or APLs A3 and S4S6 (range: 10−5–10−12 M peptide). T cell cytotoxicity
was assayed after 6 h with an effector to target cell ratio of 30:1, after which
specific lysis was calculated. Results of one (out of two) representative
experiment are shown based on the mean value of triplicate data points.
not IL-10 (Figure 4). S4S6 peptide, however, triggered maximal
production of IFNγ at concentrations that were 105–106-fold
higher when compared to wt peptide (Figure 4). Production of IL-
4 and IL-5 upon stimulation with S4S6 peptide was only detectable
at the highest peptide concentrations used (at most 750 pg/ml
when stimulating with 10−5 M peptide) (Figure 4). Using TNFα
ELISAs, in our experience more sensitive than CBA, we again only
observed detectable production of TNFα at the highest peptide
concentrations used (at most 500 pg/ml when stimulating with
10−5 M peptide) (data not shown). Lastly, activation of NFAT
was not observed for S4S6 peptide independent of the peptide
concentration tested (Figure 5).
APL S4S6-INDUCED T CELL FUNCTIONS SHOW ENHANCED
DEPENDENCY ON CD8
In an effort to explain our results with APLs A3 and S4S6, we exam-
ined their ability to bind to HLA-A2, their ability to bind (when
complexed to HLA-A2) to the gp100 TCR, and to what extent T
cell function, in case of S4S6, relies on the co-receptor CD8α.
To study HLA-A2 binding of APLs, we performed an HLA-A2
stabilization assay using T2 cells. This assay showed that APLs
A3 and S4S6 bind as efficient to HLA-A2 as does wt peptide
(i.e., stabilization factors at 50µM were 1.29, 1.14, and 1.25 for
A3, S4S6, and wt peptide, respectively). The only APLs within
our panel that bound significantly less to HLA-A2 are those that
harbored a non-conservative mutation in one of the anchoring
residues (i.e., APLs A2 and G9, but not V9, having stabilization
factors at 50µM of 0.00, 0.13, and 1.27, respectively). The abili-
ties of APLs A3 and S4S6 to be stably bound by HLA-A2 allowed
the synthesis of peptide-MHC multimers and detection of their
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FIGURE 4 |The gp100 APL S4S6 induces a changed cytokine
production profile. TCR-engineered T cells were tested for the
production of IFNγ, TNFα, IL-2, IL-4, IL-5, and IL-10 using a Cytokine Bead
Array (CBA). T2 target cells were either non-loaded or loaded with
titrated amounts of gp100 wt peptide (wt) or APLs A3 and S4S6 (range:
10−5–10−12 M peptide). Following an 18 h co-cultivation at an effector to
target cell ratio of 3:1, supernatants were collected and measured for
cytokine content. Results of one (out of three) representative
experiment are shown based on the mean value of triplicate data
points.
binding by TCR-engineered T cells by flow cytometry. When ana-
lyzing the binding of titrated amounts of peptide-HLA-A2 mul-
timers, we observed that neither A3-HLA-A2, nor (the negative
control) BMLF-1-HLA-A2 were bound by T cells (Figure 6). In
contrast, S4S6-HLA-A2 was bound by T cells, although to a lower
extent than wt peptide-HLA-A2 (Figure 6). Finally, we established
the contribution of CD8α to S4S6-induced T cell functions, to
which end we have tested T cell cytotoxicity in the presence of
a CD8α blocking antibody (Figure 7). Anti-CD8α antibody fully
neutralized gp100 TCR-mediated cytotoxicity upon stimulation
with S4S6 peptide, whereas decrease in cytolytic activity was neg-
ligible upon stimulation with wt peptide (Figure 7; right versus
left panels).
DISCUSSION
In this study, we have characterized peptide requirements for T
cell cytotoxicity, production of cytokines, and activation of NFAT.
To this end, TCRαβ genes originating from the gp100280–288-
HLA-A2-specific 296 CTL clone were transferred in human T
cells, and receptor-mediated responses were tested versus gp100-
positive and -negative melanoma cells (Figure 1) and a broad
panel of gp100 APLs (Figure 2). We observed that APLs with sin-
gle amino acid substitutions functioned as agonists. The E to A
peptide mutant (i.e., APL A3) is an exception to this observation
since it functions as a null ligand. The P to S double amino acid
substitution variant (i.e., APL S4S6) functions as a partial agonist
and is able to dissect cytotoxicity from cytokine production and
NFAT activation.
Our observation that the performance of APLs with single
amino acid substitutions was identical among the different T cell
parameters tested, i.e., T cell cytotoxicity, production of cytokines,
and activation of NFAT (Figure 2), was confirmed for a second
gp100 TCR. Primary human T cells transduced with TCRαβ genes
derived from the gp100280–288-HLA-A2-specific MPD CTL clone
(37) showed cytolytic responses which were in complete accor-
dance with TNFα production upon stimulation with APLs with
single amino acid mutations [(7), and data not shown]. In case
of the CTL-296-derived TCR, APL A3 behaved as a null agonist
with respect to T cell cytotoxicity, production of cytokines, and
activation of NFAT (Figure 2). This non-responsiveness is not
caused by less efficient presentation of A3 peptide since the bind-
ing capacity of this mutant to HLA-A2 molecules is in the same
range as that of the wt peptide. Rather, the non-responsiveness
is caused by the TCR’s inability to bind A3-HLA-A2 complexes
(Figure 6). The classification of APL A3 as a null agonist, and not
as a potentially weak or partial agonist, is justified by the observa-
tion that peptide concentrations over a 7-log range did not affect
T cell activities (Figures 3–5). In addition, we were unable to show
an inhibitory effect of excess A3 peptide on wt peptide-induced
responses in TCR-transduced human T cells, suggesting that this
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FIGURE 5 |The gp100 APL S4S6 is not able to induce activation of
NFAT. TCR-engineered Jurkat T cells were transfected with NFAT reporter
and β-galactosidase constructs and subsequently co-cultured with T2 target
cells that were either non-loaded or loaded with titrated amounts of gp100
wt peptide (wt) or APLs A3 and S4S6 (range: 10−5–10−12 M peptide).
Following a 6 h co-cultivation at an effector to target cell ratio of 2:1, lysates
were collected and measured for luciferase activities [depicted as light units
(LU) corrected for medium only]. Results of one (out of two) representative
experiment are shown based on the mean value of triplicate data points.
peptide variant is not acting as an antagonist (data not shown).
The possibility that APL A3 acts as a supra-agonist, i.e., a null
ligand that enhances the reactivation of memory CTL responses
(38), is currently under investigation.
Altered peptide ligand S4S6 was classified as a partial agonist
since it was able to induce cytotoxicity, production of only selected
cytokines, but not activation of NFAT when compared to wt pep-
tide (Figures 3–5). When using titrated amounts of peptide we
demonstrated that 10–100-fold more S4S6 peptide was needed
to induce cytotoxicity when compared to wt peptide (Figure 3).
The decreased sensitivity of TCR-mediated cytotoxicity was rela-
tively minor and at least a 1000-fold less when compared to the
decreased sensitivities of TCR-mediated cytokine production and
NFAT activation for S4S6 versus wt peptide (see below). Induc-
tion of cytotoxic activity is considered an early T cell response and
generally requires small amounts of antigenic peptide and hardly
any TCR down-regulation. Cytolytic proteins, e.g., perforin and
granzymes, are pre-synthesized and thereby lower the threshold
to trigger their release, which may explain the success of partial
agonists to induce cytotoxicity (39–43). S4S6 peptide induced the
production of IFNγ and to a lesser extent of IL-4, IL-5, and TNFα,
but not IL-2 and IL-10 (Figure 4) or the activation of NFAT
(Figure 5). In fact, TCR-mediated production of IFNγ required
105–106-fold higher concentrations of S4S6 when compared to wt
peptide, and production of IL-4, IL-5, and TNFα required >106-
fold higher concentrations of S4S6, whereas production of IL-2,
IL-10, and activation of NFAT could not even be measured at
the highest concentration of S4S6 tested. These findings are in
line with the notion that de novo synthesis of cytokines, which in
FIGURE 6 | DifferentialT cell responsiveness toward gp100 APLs is
related toTCR’s ability to bind gp100/HLA-A2 complexes.
TCR-engineeredT cells were stained with titrated amounts of PE-conjugated
peptide-MHC multimers (range: 400–12,5 nM peptide-MHC complexes)
and analyzed via flow cytometry. The gp100-HLA-A2 multimers comprise
either gp100 wt peptide or APLs A3 and S4S6. The BMLF-1-HLA-A2
multimer served as a negative control. Binding of peptide-MHC multimers
is analyzed as described in Section “Flow Cytometry and Cell-Sorting” and
indicated in percentage. Percentages correspond to marker-positive T cells.
Results of one (out of two) representative experiment are shown based on
the mean value of triplicate data points.
FIGURE 7 |The gp100 APL S4S6 renders the gp100/HLA-A2-specificTCR
CD8 dependent. TCR-engineered T cells were tested in a 51Cr-release assay
as described in legend to Figure 3 either without or with blocking anti-CD8
mAb (left and right panels, respectively). T2 cells were either non-loaded or
loaded with titrated amounts of gp100 wt peptide (wt) or APLs A3 and S4S6
(range: 10−6–10−9 M peptide). Results of one (out of two) representative
experiment are shown based on the mean value of triplicate data points.
many cases depends on NFAT activation, generally requires higher
amounts of antigenic peptide and a much stronger TCR signal,
i.e., high levels of TCR occupancy and TCR down-regulation (43).
Production of cytokines and activation of NFAT, considered late T
cell responses, may therefore not be triggered by a partial agonist.
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Partially agonistic peptides can selectively stimulate some T cell
effector functions by inducing a pattern of signal transduction that
is qualitatively different from the pattern induced by any concen-
tration of the native peptide (9, 44–46). Partial agonistic signaling
patterns are characterized by differential phosphorylation of TCR
subunits, recruitment but no activation of ZAP-70, activation of
MAP kinases (although for a shortened time period) and/or phe-
notypically distinct Ca2+ fluxes (11, 47, 48). A shortened period of
MAP kinase activation and/or weakened Ca2+ flux could explain
the observed lack of NFAT activation in T cells following stim-
ulation with S4S6 peptide. Translocation of NFAT is reported to
take place during “the TCR and co-receptor microclustering stage”
in the formation of an immunological synapse (49). It would be
interesting to find out whether S4S6 peptide would allow for TCR
engagement but not proceeding to TCR microclustering and/or
its coalescence into a central synapse. Another property of APL
S4S6 may include its potential ability to induce T cell anergy. This
state of T cell hyporesponsiveness is generally induced by trigger-
ing the TCR in the absence of sufficient T cell co-stimulation or in
the presence of proficient T cell co-inhibition, and accompanied
by the expression of anergy-associated genes, which subsequently
contributes to impaired TCR signaling (50). Although there exist
multiple forms of anergy, and it is mainly studied in CD4 T cells,
the induction of anergy-associated genes appears to depend on the
activation of NFAT. Hence, we argue that APL S4S6, because of its
inability to activate NFAT, does not contribute to an anergic state
of T cells.
The partial T cell responsiveness induced by APL S4S6 is not
related to an altered ability of S4S6 peptide to bind to HLA-
A2, but rather to a substantially decreased ability of the gp100
TCR to bind S4S6-HLA-A2 complexes (Figure 6). The new Ser-
ine residues, although not affecting binding to HLA-A2, appar-
ently changed peptide-MHC conformation such that TCR chains
showed a decreased fit for APL S4S6. Interestingly, APLs A2 and
G9 with non-conservative amino acid substitutions at one of the
peptide anchor positions to bind to HLA-A2 showed a significantly
lowered stabilization of HLA-A2, yet were clearly able to induce
cytotoxicity, TNFαproduction, and activation of NFAT (Figure 2).
This apparent discrepancy most likely suggests that the CTL-296-
derived TCR is of high affinity and that only a few peptide-loaded
MHC class I molecules are needed to induce T cell activation.
This would, in turn, further argue in favor of a dominant role for
the interaction between peptide-MHC and TCR when compared
to the interaction between peptide and MHC. Since the CD8α
co-receptor can contribute to the stability of TCR:pMHC interac-
tions and may, at least in part, compensate for a lowered affinity
of a TCR for peptide-MHC (51, 52), we addressed whether S4S6
and wt peptide differed with respect to the CD8α-dependency of
T cell cytotoxicity. In line with a decreased recognition by gp100
TCR, we observed that T cell responses toward APL S4S6 showed
an enhanced involvement of CD8α (Figure 7). These observa-
tions extend those of Laugel and colleagues, who reported that T
cell activation induced by strong, but not weak or partial ago-
nists, does occur without CD8 co-activation (52). In fact, our
results with APL S4S6 may suggest that the agonist potential of
peptide mutants relates to the extent of binding by TCR and
CD8α, a hypothesis that should be tested for multiple partial
agonists.
Taken together, we have studied a novel panel of APLs in the
context of TCR-engineered T cells and identified gp100280–288
APLs that act either as full agonists, a null ligand, or a partial ago-
nist. In addition, our findings dissected T cell cytotoxicity from
T cell cytokine production and NFAT activation and revealed
that early T cell responses may require less peptide-MHC when
compared to late T cell responses. Notably, our data suggest
that partial agonists show a decreased binding by TCR and an
enhanced dependency on CD8α, which may represent a novel
mechanism behind the properties of partial agonists. Building
on the current report, further design and testing of additional
APLs may be necessary to advance the therapeutic application of
APLs.
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